<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110001</url>
  </required_header>
  <id_info>
    <org_study_id>18-26045-R</org_study_id>
    <secondary_id>UG1EY028518</secondary_id>
    <nct_id>NCT05110001</nct_id>
  </id_info>
  <brief_title>Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction</brief_title>
  <acronym>REAGIR</acronym>
  <official_title>Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas M. Lietman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aravind Eye Care System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR ) is&#xD;
      an international, randomized, doubled masked, clinical trial. The purpose of this study is to&#xD;
      determine differences in 6-month visual acuity between medical antimicrobial treatments alone&#xD;
      versus antimicrobial treatment plus cross-linking with rose Bengal (RGX).&#xD;
&#xD;
      Patients presenting to one of the Aravind Eye Hospitals in India or to the University of&#xD;
      California San Francisco (UCSF) with either smear or culture positive fungal or acanthamoeba&#xD;
      keratitis or smear and culture negative corneal ulcers and moderate to severe vision loss,&#xD;
      defined as Snellen visual acuity of 20/40 or worse, will be eligible for inclusion. Those who&#xD;
      agree to participate will be randomized to one of two treatment groups:&#xD;
&#xD;
      Group 4, Sham RGX: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5%&#xD;
      (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RGX&#xD;
&#xD;
      Group 5, RGX: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5%&#xD;
      (smear/culture negative) or natamycin 5% (fungal keratitis) plus RGX.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity</measure>
    <time_frame>6 Months</time_frame>
    <description>Best Spectacle-Corrected Visual Acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity</measure>
    <time_frame>3 Weeks, 3 Months, 12 Months</time_frame>
    <description>Best Spectacle-Corrected Visual Acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar Size</measure>
    <time_frame>3 Weeks, 3 Months, 6 Months 12 Months</time_frame>
    <description>Geometric Mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar Depth</measure>
    <time_frame>3 Weeks, 3 Months, 6 Months 12 Months</time_frame>
    <description>Geometric Mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Acanthamoeba Keratitis</condition>
  <condition>Fungal Keratitis</condition>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RGX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-Linking with rose Bengal(RGX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RGX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Ophthalmic</intervention_name>
    <description>Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.</description>
    <arm_group_label>Cross-Linking with rose Bengal(RGX)</arm_group_label>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine Gluconate</intervention_name>
    <description>Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.</description>
    <arm_group_label>Cross-Linking with rose Bengal(RGX)</arm_group_label>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natamycin</intervention_name>
    <description>Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.</description>
    <arm_group_label>Cross-Linking with rose Bengal(RGX)</arm_group_label>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rose Bengal</intervention_name>
    <description>Study participants receive RGX within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.2% RB in BSS) which will be applied in 5-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected 30 minutes after the procedure.</description>
    <arm_group_label>Cross-Linking with rose Bengal(RGX)</arm_group_label>
    <other_name>Corneal Cross Linking with rose Bengal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study participants receive sham RGX within 48 hours of randomization. Participants will receive a 30-minute loading dose of topical balanced salt solution which will be applied in 5-minute intervals to the de-epithelialized cornea. A pen light covered with a green filter will be used for 15 minutes. Repeat cornea culture will be collected 30 minutes after the sham procedure.</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of smear or culture positive fungal or acanthamoeba ulcer; smear or culture&#xD;
             negative ulcer; or any atypical bacteria (such as Nocardia)&#xD;
&#xD;
          -  Moderate to severe vision loss, defined as Snellen visual acuity of 20/40 (6/12) or&#xD;
             worse&#xD;
&#xD;
          -  Corneal thickness ≥350 µm, as measured on AS-OCT&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Basic understanding of the study as determined by the physician&#xD;
&#xD;
          -  Commitment to return for follow up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of concomitant infection on exam, gram stain, or confocal microscopy (i.e.&#xD;
             herpes, both bacteria and acanthamoeba on gram stain)&#xD;
&#xD;
          -  Impending or frank perforation at recruitment&#xD;
&#xD;
          -  Involvement of sclera at presentation&#xD;
&#xD;
          -  Non-infectious or autoimmune keratitis&#xD;
&#xD;
          -  History of corneal transplantation&#xD;
&#xD;
          -  History of intraocular surgery within last three months&#xD;
&#xD;
          -  Pinhole visual acuity worse than 20/200 in the unaffected eye&#xD;
&#xD;
          -  Participants who are decisionally and/or cognitively impaired&#xD;
&#xD;
          -  Presence of demestocele at recruitment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Lietman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Frnasco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Rose-Nussbaumer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole Varnado, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom Lietman, MD</last_name>
    <phone>415-502-2662</phone>
    <email>tom.lietman@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Rose-Nussbaumer, MD</last_name>
    <email>rosej@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicole E Varnado, MPH</last_name>
      <email>nvarnado@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Francis I. Proctor Foundaiton</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tom Lietman, MD</last_name>
      <phone>415-502-2662</phone>
      <email>tom.lietman@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Cavallino, MSPH</last_name>
      <phone>6195406557</phone>
      <email>victoria.cavallino@ucsf.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Care System</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>N V Prajna</last_name>
      <email>prajna@aravind.org</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas M. Lietman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acanthamoeba Keratitis</mesh_term>
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Natamycin</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

